Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience

Abstract

Few publications exist concerning allogeneic hematopoietic cell transplant (alloHCT) outcomes in non-Japanese patients with HTLV-1-associated ATLL. We detail the patient and disease characteristics, transplant approach, and clinical outcomes in 17 patients with ATLL at our institution who underwent alloHCT. We report favorable outcomes, with 8/17 in ongoing remission, 2/17 with prolonged (>6 years) disease-free survival, and a low incidence of transplant-related mortality (2/17). These results validate the feasibility and efficacy of alloHCT in non-Japanese patients with ATLL.

Keywords:

• Adult T-cell leukemia lymphoma
• allogeneic stem cell transplantation

Acknowledgements

We gratefully acknowledge the assistance of Natasha Galasso, Molly Maloy, and Josel Ruiz. Z.D.E-P is a recipient of an AACR-AstraZeneca Research Fellowship.

Disclosure statement

• A.K. receives research funding from Abbvie, Adaptive Biotechnologies, Celgene, Pharmacyclics, and Seattle Genetics; member of the advisory board for Celgene, Kite Pharma, AstraZeneca and the Summit Advisory Committee; has served on the steering committee for the MCL Registry with AstraZeneca.

• D.M.P. serves as a consultant on scientific advisory board for Generon Corporation, paid consultant on scientific advisory boards of Kadmon Corporation, Ceramedix; paid consultant and received honorarium from CareDx; she has received research funds for clinical trial from Takeda Pharmaceutical.

• C.S.S. has served as a paid consultant on advisory boards for: Juno Therapeutics, Sanofi-Genzyme, Spectrum Pharmaceuticals, Novartis, Genmab, Precision Biosciences, Kite/a Gilead Company, Celgene, Gamida Cell and GSK. He has received research funds for clinical trials from: Juno Therapeutics, Celgene, Precision Biosciences and Sanofi-Genzyme.

• M.-A.P. has received honoraria from AbbVie, Bellicum, BMS, Incyte, Merck, Novartis, Nektar Therapeutics, Omeros, and Takeda; serves on data safety and monitoring boards for Servier and Medigene and on scientific advisory boards of MolMed and NexImmune; and has received research support for clinical trials from Incyte, Kite Pharma/Gilead, Miltenyi Biotec, and Novartis.

• P.B.D. serves on the advisory board for Kite/a Gilead Company.

• A.N. serves on the advisory board for Janssen and Morphosys, has received honoraria from Medscape, has received research funding and honoraria from Pharmacyclics, and has received research funding from Rafael Pharma.

• S.A.G. received research funding from Actinnum, Celgene, Bristol-Myers Squibb, Sanofi, Amgen, Pfizer, and Jensenn; and serves on the advisory board for Actinnum, Celgene, Bristol-Myers Squibb, Sanofi, Amgen, Pfizer, GlaxoSmithKline, Jazz, and Jensenn.

• A.J.M has received research support from Miragen, Seattle Genetics, Merck, Bristol-Myers Squibb, and Incyte; and honoraria from Imbrium Therapeutics L.P., Purdue Pharma L.C., Merck, and Seattle Genetics.

• S.H. has consulted, received honorarium from, or participated in advisory boards for; ADC Therapeutics, C4 Therapeutics, Celgene, Janssen, Kura Oncology, Kyowa Hakko Kirin, Myeloid Therapeutics, Seattle Genetics, Takeda, Verastem, and Vividion Therapeutics and has received research support for clinical trials from ADC Therapeutics, Aileron, Celgene, Daiichi Sankyo, Forty Seven, Inc., Kyowa Hakko Kirin, Millennium/Takeda, Portola Pharmaceuticals, Seattle Genetics, Trillium Therapeutics, and Verastem.

• All other authors declare no commercial affiliations, consultancies, stock or equity interests, or patent-licensing arrangements that could be considered to pose a conflict of interest regarding the submitted article.

Additional information

Funding

This work was supported by an institutional grant from the National Cancer Institute (P30 CA008748).